In reply: Sugammadex in end-stage renal disease: too early for a “free-pass”

Renew, J. Ross; Porter, Steven B.; Porter, Ivan; Paredes, Stephania

doi:10.1007/s12630-020-01861-8

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the number of clinical studies reported to date is limited [2,[11][12][13][14][15], and only a few case reports have been reported [8,18,19]. Nevertheless, the demand and need for the administration of rocuronium and sugammadex in ESRD patients in actual clinical practice is increasing, and several recently reported retrospective studies dispute this need [6,7,16,20]. Therefore, considering that there is an increasing need to evaluate the efficacy and safety of sugammadex in patients with ESRD, we tried, systematically and closely, to examine the efficacy and safety of the administration of rocuronium and sugammadex in ESRD patients, using a systematic review framework as far as this is possible.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Sugammadex is widely used in anesthesia to reverse rocuronium-induced neuromuscular blockade (NMB). In patients with compromised kidney function, most drugs show alteration of their pharmacokinetic profile with reduced clearance. The purpose of this article is to examine the efficacy, pharmacokinetics, and safety of sugammadex in end-stage renal disease (ESRD) patients receiving general anesthesia, using a systematic review. Materials and Methods: The databases of PubMed, EMBASE, the Cochrane Library, Web of Science, Scopus, KoreaMed, and ClinicalTrials.gov were searched for studies comparing the efficacy or safety outcomes of sugammadex administration for the reversal of rocuronium-induced NMB, in ESRD patients (group R) or in those with normal renal function (group N) undergoing surgery under general anesthesia. Results: We identified nine studies with 655 patients—six prospective, case-control studies with 179 patients (89 and 90 in groups R and N) and three retrospective observational studies with 476 ESRD patients. In the six prospective studies, the times taken to reach a train-of-four ratio ≥0.9, 0.8, and 0.7 were significantly longer in group R than in group N (weighted mean difference [95% confidence interval] [min]: 1.14 [0.29 to 2.00], 0.9 [0.24 to 1.57], 0.89 [0.20 to 1.57], respectively). The total plasma clearance of sugammadex was significantly lower in group R than in group N. There was no significant difference in the incidence of NMB recurrence and prolonged time to recovery between the groups. In the three retrospective studies, the possibility of sugammadex-related adverse events appears to be insignificant. Conclusions: Sugammadex may effectively and safely reverse rocuronium-induced NMB in patients with ESRD, although the recovery to a TOF ratio of 0.9 may be prolonged compared to patients with normal renal function. Further studies are needed, considering the small number of studies included and the high heterogeneity of some of the results.

show abstract